Enterprise Value to EBITDA Ratio: Elevation Oncology (ELEV)
Elevation Oncology (ELEV) develops targeted biologics, leveraging an extensive network of research centers to protect profits. This chart illustrating the price evolution shows that the EV/EBITDA multiple is fixed at . The company's high authority among physicians is driven by its success in tumor therapy, while specific demand for treatment renders the asset immune to economic crises or inflationary shocks.
ELEV (Elevation Oncology Inc.): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Elevation Oncology|ELEV - Long-Term Liabilities to Capital|Short-Term Debt to Equity Elevation Oncology|ELEV - Company Debts|Debts to Book Capitalization Elevation Oncology, Inc.|ELEV - Long-Term Debt|Company Current Liabilities Elevation Oncology|Quick Ratio elevationoncology.com
- business earnings and investment ratios data:
ELEV - Net Profit|Future Profit Elevation Oncology|ELEV - Market Price to Net Income Ratio|Forward P/E Multiple Elevation Oncology, Inc.|ELEV - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Elevation Oncology, Inc.|ELEV - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Elevation Oncology|ELEV - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months elevationoncology.com|ELEV - Earnings per share increase in current year|Net earnings per share growth forecast for next year Elevation Oncology
Summary company analytics:Elevation Oncology, Inc. ELEV
This metric combines market capitalization and net debt, comparing the total enterprise value to operating profit before depreciation and amortization. Such a methodology strips the valuation of accounting distortions, allowing for the determination of the real value of assets relative to their ability to generate cash flow. For Elevation Oncology (ELEV), which utilizes outsourced manufacturing, the company's EV/EBITDA ratio over the time series demonstrates capital management efficiency without the burden of heavy fixed assets.
Competitor analysis
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|DCTH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Aura Biosciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Candel - EV/EBITDA Multiple|Company Value to EBITDA Accuray, Inc.|SLS (sellaslifesciences.com) - Enterprise Value to EBITDA Ratio|ACTU (actuatetherapeutics.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CTOR (Citius Oncology) - EV/EBITDA Multiple|EV/EBITDA Multiple TuHURA|Enterprise Value to EBITDA Ratio TARA (Protara)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (Aadi Bioscience)|Total Company Value to Operating Income Before Depreciation Ratio TScan Therapeutics Inc (TCRX)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA XBiotech Inc.|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OSTX|Enterprise Value to EBITDA Ratio RADX|ARTV: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adlai Nortye Ltd. (ANL)|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|XLO: Enterprise Value to Operating Income Before Depreciation|Enochian BioSciences - EV/EBITDA Multiple|Mural Oncology plc (MURA) - Enterprise Value to EBITDA Ratio|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA OnKure Therapeutics (OKUR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytoMed Therapeutics Ltd|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CRIS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc. (APLM)|THAR - Company Value to EBITDA|EV/EBITDA Multiple ADVB (Advanced Biomed)|Enterprise Value to EBITDA Multiple Genprex Inc.|CLDI: Enterprise Value to EBITDA Ratio|Company Value to EBITDA sunshinebiopharma.com|XBIO: EV/EBITDA Multiple|Company Value to EBITDA salariuspharma.com (SLRX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Purple Biotech Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AONC|EV/EBITDA Multiple BGNE|CKPT - Company Value to EBITDA|iCAD - Enterprise Value to EBITDA Ratio|Ikena Oncology Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
